Cancer drugs costs 30% less than thought
A Cornell study finds that the true cost of cancer drugs is 30% less than a decade ago, once longevity and quality of life are considered.
Cornell University researchers have found that the true cost of cancer drugs is 30% less than a decade ago, once longevity and quality of life are considered, in a study released last week.
“A Quality-Adjusted Price Index for Colorectal Cancer Drugs,” published by National Bureau of Economic Research (NBER), draws on the experiences of thousands colon cancer patients and treatment decisions by oncologists nationwide.
Cornell’s researchers analyzed the real-world treatment data collected through clinical software. New drugs, like Avastin and Erbitux, are boosting survival rates.
Today’s leading drugs for colorectal cancer are typically used in new and constantly evolving combinations, which increase the efficacy of treatments and the options available to more patients.
Patients treated with one popular combination report a mean survival of 23.2 months, compared with the mean survival rate of 12.5 months when patients received just one of the drugs which was the standard of care in 1996. The early treatments were effective for just a small percentage of the patient population.
One of the combinations studied by the Cornell team is bevacizumab (Avastin) + oxaliplatin (Eloxatin) + 5-FU/leucovorin.
Today’s most commonly prescribed 24-week course of treatment costs an average of $36,000, a dramatic increase over the price of a decade ago. Yet the Cornell study shows that adjusting cost for quality-accounting for the far greater efficacy of today’s treatments-prices have actually declined.
The Cornell study begins by estimating the financial value that physicians place on eight different attributes of a chemotherapy drug, such as the average number of months that patients live if they are taking the drug, or the percentage of patients that experience a severe side effect. Researchers then create a price index by applying these physician value assessments to changes in drug attributes between 1993 and 2005.
“Instead of focusing on the cost of a specific drug dosage cost, cancer or otherwise, it is essential that we look at the big picture costs that include all aspects of quality of life,” says Peggy C. Frank, MBA CEO, Frank Public Relations Worldwide, Westlake Village, Calif.
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
